Kinetics of Antibodies Against Adalimumab Are Not Associated With Poor Outcomes in IBD

@article{Paul2015KineticsOA,
  title={Kinetics of Antibodies Against Adalimumab Are Not Associated With Poor Outcomes in IBD},
  author={St{\'e}phane Paul and William Dronne and Xavier Roblin},
  journal={The American Journal of Gastroenterology},
  year={2015},
  volume={110},
  pages={777-778}
}
and immunological prospective database, which included all patients followed up at the gastroenterology department. Eligible patients were defi ned as patients treated with adalimumab (ADA) at a maintenance dose (40 mg eow sc) without any concomitant treatment. Patients must also present, at the beginning of the kinetics study, undetectable trough level of adalimumab (TRA <0.1 μ g/ml) measured by enzyme-linked immunosorbent assay (ELISA) (Th eradiag, Marne-la-Vallée, France) and at least three… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

References

Publications referenced by this paper.
Showing 1-3 of 3 references

Th e temporal evolution of antidrug antibodies in patients with infl ammatory bowel disease treated with infl iximab

  • B Ungar, Y Chowers, M Yavzori
  • Gut
  • 2014